A Prospective, Single-arm, Open-Label, Phase II Study of Nab-paclitaxel Plus Cisplatin Plus Carilizumab as First-line Treatment in Patients With Metastatic Triple-negative Breast Cancer
To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin plus carilizumab as first-line treatment in patients with metastatic triple-negative breast cancer.
• Female patients aged 18-70 years who had
• Metastatic TNBC. ER, PgR, and HER2 status were determined locally by immunohistochemistry (IHC) of patient primary or metastatic tumor sections. Metastatic disease was confirmed by clinical, imaging, histological or cytological measures.
• Patients were required to receive no previous chemotherapy or targeted therapy for metastatic triple-negative breast cancer.
• Patients who had received adjuvant/neoadjuvant therapy were required an interval for at least 6 months after stop of chemotherapy before the enrollment.
• At least one measurable lesion according to RECIST 1.1,
• ECOG performance status ≤ 1
• Life expectancy of more than 12 weeks
• Adequate organ and bone marrow function.